Establishment of the combined treatment of hematopoietic stem cells transplantation and S100A6 inhibitors to KMT2A/AFF1 positive acute lymphoblastic leukemia

Research Project

Project/Area Number	23K06776
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 50020:Tumor diagnostics and therapeutics-related
Research Institution	St. Marianna University School of Medicine
Principal Investigator	玉井勇人聖マリアンナ医科大学, 医学部, 准教授 (40465349)
Project Period (FY)	2023-04-01 – 2026-03-31
Project Status	Granted (Fiscal Year 2023)
Budget Amount *help	¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2025: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000) Fiscal Year 2024: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2023: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	S100A6 / KMT2A / MLL / 急性リンパ性白血病 / Amlexanox
Outline of Research at the Start	難治性白血病であるKMT2A/AFF1陽性急性リンパ性白血病は、Ca結合蛋白であるS100A6を発現して造血幹細胞移植後のGraft versus Leukemia effectを逃れている。S100A6発現を阻害するAmlexanox併用造血幹細胞移植でKMT2A/AFF1陽性ALLに治癒をもたらす可能性を検証する。